All In Biotech

Drug Trial Radar · NCT00761358

To Verify the Efficacy of Z-338 in Subjects With Functional Dyspepsia

To Verify the Efficacy of Z-338 in Subjects With Functional Dyspepsia, Focusing on the Assessment of Subjective Symptoms

Last checked: Nov 19, 2026Latest source record: Nov 23, 2010 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 820 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

820

Planned (sponsor's estimate)

Start

Sep 2008

Primary completion

Jun 2010

Study completion Aug 2010

Sponsor

Lead sponsor
Zeria PharmaceuticalIndustry
Sponsor type
Industry
First posted
Sep 29, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 20 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to verify the superior efficacy of Z-338 to placebo in subjects with Functional Dyspepsia, focusing on the assessment of subjective symptoms.

Conditions

  • Functional Dyspepsia

Interventions

  • Z-338Drug

    Oral

  • PlaceboDrug

    Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. General impression at last visit in treatment periodTime frame: 4 week
  2. Elimination rate of post-prandial fullness, upper abdominal bloating and early satiety at last visit in treatment periodTime frame: 4 week

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Hokkaido, Japan

  • Site not named

    Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.